1. Home
  2. REE vs LNAI Comparison

REE vs LNAI Comparison

Compare REE & LNAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo REE Automotive Ltd.

REE

REE Automotive Ltd.

HOLD

Current Price

$0.67

Market Cap

21.7M

ML Signal

HOLD

Logo Lunai Bioworks Inc.

LNAI

Lunai Bioworks Inc.

N/A

Current Price

$0.82

Market Cap

20.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
REE
LNAI
Founded
2011
N/A
Country
Israel
United States
Employees
N/A
N/A
Industry
Auto Manufacturing
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.7M
20.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
REE
LNAI
Price
$0.67
$0.82
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$11.75
N/A
AVG Volume (30 Days)
132.2K
182.3K
Earning Date
03-16-2026
02-18-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$207,000.00
N/A
Revenue This Year
$327.73
N/A
Revenue Next Year
$36,888.82
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.53
$0.79
52 Week High
$9.53
$14.00

Technical Indicators

Market Signals
Indicator
REE
LNAI
Relative Strength Index (RSI) 37.14 40.06
Support Level $0.69 $0.79
Resistance Level $0.78 $0.97
Average True Range (ATR) 0.07 0.08
MACD -0.01 -0.00
Stochastic Oscillator 21.31 27.02

Price Performance

Historical Comparison
REE
LNAI

About REE REE Automotive Ltd.

REE Automotive Ltd is an automotive technology company focused on building commercial electric vehicles controlled fully by-wire. The company is in early stages of commercialization and develop and produce software-defined vehicle (SDV) technology that manages vehicle operations and features through proprietarily-developed software. The company has geographical preference in Israel, Germany, United States, United Kingdom, and other regions.

About LNAI Lunai Bioworks Inc.

Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.

Share on Social Networks: